Bcr-Abl 酪氨酸激酶抑制剂的肺部并发症
本文综述靶向 Bcr-Abl 的酪氨酸激酶抑制剂(TKI)相关肺部并发症。达沙替尼最常引起肺部并发症,胸腔积液最常见,肺动脉高压少见但严重且停药后常可逆;伊马替尼主要与罕见间质性肺病相关;机制上达沙替尼经线粒体氧化应激损伤肺内皮。
要点
- 达沙替尼最常相关肺部并发症,胸腔积液最常见,肺动脉高压少见但严重且停药后常可逆
- 博舒替尼和帕纳替尼亦与肺动脉高压相关,伊马替尼未报告相关;间质性肺病罕见,主要见于伊马替尼
- 需提高对 TKI 肺部并发症的认识并早期诊断,因其严重、可能可逆且影响后续治疗选择
核心结论
- Bcr-Abl TKI 可引起多种肺部并发症,达沙替尼相关者最常见,早期识别很重要。
研究设计与样本
- 综述类文章,总结 Bcr-Abl TKI 肺部并发症的临床谱与机制,未报告检索范围与样本量。
主要发现
- 胸腔积液是 TKI 最常见的肺部并发症,通常与达沙替尼和博舒替尼相关。
- 肺动脉高压是达沙替尼少见但严重的并发症,停药后常可逆。
- 博舒替尼和帕纳替尼亦与肺动脉高压相关,伊马替尼未报告相关。
- 间质性肺病罕见与 TKI 相关,主要见于伊马替尼。
- 达沙替尼经线粒体氧化应激、诱导内皮凋亡及剂量依赖性损害血管通透性影响肺内皮完整性。
临床怎么用
- 对使用 Bcr-Abl TKI 的慢性髓性白血病患者应警惕胸腔积液、肺动脉高压和间质性肺病,及早识别并评估停药可能。
局限性
- 除达沙替尼外,其他 TKI 相关并发症的机制大部分未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukaemia. Following the success of imatinib, second- and third-generation molecules were developed. Different profiles of kinase inhibition and off-target effects vary between TKIs, which leads to a broad spectrum of potential toxicities.Pulmonary complications are most frequently observed with dasatinib but all other Bcr-Abl TKIs have been implicated. Pleural effusions are the most frequent pulmonary complication of TKIs, usually associated with dasatinib and bosutinib. Pulmonary arterial hypertension is an uncommon but serious complication of dasatinib, which is often reversible upon discontinuation. Bosutinib and ponatinib have also been associated with pulmonary arterial hypertension, while imatinib has not. Rarely, interstitial lung disease has been associated with TKIs, predominantly with imatinib.Mechanistically, dasatinib affects maintenance of normal pulmonary endothelial integrity by generating mitochondrial oxidative stress, inducing endothelial apoptosis and impairing vascular permeability in a dose-dependent manner. The mechanisms underlying other TKI-related complications are largely unknown. Awareness and early diagnosis of the pulmonary complications of Bcr-Abl TKIs is essential given their seriousness, potential reversibility, and impact on future treatment options for the underlying chronic myelogenous leukaemia.
引用
- Weatherald J, Bondeelle L, Chaumais MC, et al. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. Eur Respir J. 2020. PMID: 32527740. doi:10.1183/13993003.00279-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。